Markers in blood predict severe COVID-19 infection
When attempting to predict who will end up in the ICU with COVID-19, the answer flows in the blood. Until now, there was no definitive way to chart a patient’s course, but there are known risk factors, like obesity, high blood pressure and diabetes.Source: WGNTV
Strategies to accelerate diagnosis and treatment of rare cardiovascular diseases
The current landscape for patients with rare cardiovascular disease has shifted. Using genome sequencing Yale physician-scientists have begun to elucidate the pathophysiology of genetic disorders and develop treatment guidelines and recommendations.
Mining Brain Metastasis for Answers
When lung cancer and breast cancer relapse, they often metastasize in the brain. The tumors that arise in the brain develop novel characteristics, differences that oft en confer resistance to existing drug therapies and create opportunities for new detection and treatment approaches for Yale Cancer Center researchers.
Rallying Resources Around DNA Repair Research
When it comes to unlocking the secrets of DNA repair, Yale Cancer Center has an armamentarium at work. In the last two years, Yale’s team has made significant advances in targeting the BRCA-dependent DNA repair axis for cancer therapy and determined that both BRCA1 and BRCA2 protein are involved in DNA repair, but they have fundamentally different mechanisms.
Diverse Junior Scientists Display Their Talents and Learn to Navigate Academia
The fellows largely represented communities that have been historically unrepresented in the field of medical research, including those from ethnic and racial minorities, those with disabilities, those from low socioeconomic backgrounds, women, or those who identify as LGBTQI+.
Winners Announced for Annual Yale Cancer Center Conclave Awards
Yale Cancer Center held its annual Conclave award ceremony virtually on January 26th to celebrate faculty and provider accomplishments 2020. Faculty and staff were honored with clinical and research prizes including the Ruth McCorkle Oncology Advanced Practice Provider Award, the Class of ‘61 Cancer Research Award, and the Yale Cancer Center Lifetime Achievement Award.
'Cellular Chatter': Researchers Aim to Decode Communications Within a Tumor
Inside a tumor, chatter abounds. Multiple cell types are constantly communicating with each other, exchanging various types of information. Some are working together against the tumor, while others help the tumor grow. Researchers have a good handle on who the main players are, but it can be difficult to tell the good ones from the bad ones, and who’s communicating with whom. To make things even more complicated, sometimes good cells turn bad — and researchers don’t know why.
Are there COVID-19–related ‘long-haul’ skin issues?
“I’m not sure there is a definitive correct answer, definitely not that everyone would agree on,” said Christine Ko, MD, professor of dermatology and pathology at Yale University, New Haven, Conn. Dr. Freeman, however, believed that pernio and especially persistent lesions are caused by an immune response to COVID. In an interview, she noted the multiple cases of patients in the registry who did seroconvert and that, while a registry is not a perfect means of getting an answer, it is good for generating questions. Taken collectively, the cases in the registry can “tell a story for further hypotheses,” said Dr. Freeman, who is director of global health dermatology at Massachusetts General Hospital and assistant professor of dermatology at Harvard University, both in Boston.Source: The Hopsitalist
Yale researchers find first cases of new UK coronavirus variant in Connecticut
Gov. Ned Lamont on Jan. 7 announced that Yale researchers in collaboration with the Connecticut Department of Public Health (DPH) detected the first two cases of the SARS-CoV-2 variant B.1.1.7 in the state. This is the same variant initially discovered in the United Kingdom that is associated with increased transmission.Source: Yale News
National Women’s Hockey League Partners with Yale on COVID-19 Testing
The PCR viral RNA testing method — known as SalivaDirect — was developed by researchers at the Yale School of Public Health (YSPH). It was granted an emergency use authorization by the U.S. Food and Drug Administration after researchers performed clinical validation in collaboration with YSPH, Yale New Haven Hospital, and Yale Pathology Labs (YPL).Source: YaleNews
National Women's Hockey League Partners with Yale on COVID-19 Testing
The National Women's Hockey League is working with Yale to provide saliva-based COVID-19 testing for players and staff during the upcoming season and Isobel Cup Playoffs in Lake Placid. The PCR viral RNA testing method - known as SalivaDirect™ - was developed by researchers at the Yale School of Public Health (YSPH). It was granted an emergency use authorization by the U.S. Food and Drug Administration after researchers performed clinical validation in collaboration with YSPH, Yale-New Haven Hospital, and Yale Pathology Labs (YPL). "YPL was the first to offer SalivaDirect™ to the public and the National Women's Hockey League is the first women's professional sports league to implement SalivaDirect™ testing," said Stephanie Weirsman, physician liaison for YPL. photo credit: Kate FreseSource: National Women's Hockey League (NWHL)